OasisLMS

This product is: 

• Free for conference attendees.
• Available for purchase for those that did NOT attend the conference. 

For assistance, email: education@iaslc.org

Presentation Slides and Recordings will be uploaded as they are ready. Individual recordings will be uploaded at a later date.

The IASLC 2025 Hot Topic Meeting: Unraveling Precancer and Early-Stage Lung Cancer is a biannual international meeting dedicated to the latest preclinical and translational advances in the earliest phases of lung carcinogenesis. This meeting brings together leading scientists, clinicians, and multidisciplinary experts to explore the biological foundations of precancerous lesions and early-stage lung tumors.

The program offers a comprehensive examination of the molecular and cellular mechanisms that initiate and drive early lung cancer development, including emerging biomarkers, novel diagnostic strategies, and evolving models of tumor evolution and progression. Sessions spanning diverse topics from early detection biology and immunologic shifts to single-cell analyses, therapeutic vulnerabilities, and precision interception approaches, provide attendees with deep insight into both the scientific underpinnings and potential clinical applications.

By emphasizing the continuum from discovery science to early intervention, this meeting equips laboratory researchers, translational investigators, and clinicians with the knowledge needed to advance personalized strategies for early detection, risk stratification, and treatment. Attendees will have the opportunity to engage with global experts, gain awareness of cutting-edge research and ongoing clinical translation, and contribute to a shared mission of improving outcomes for patients at the earliest points of lung cancer care.

The meeting is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses.

Upon completion of this activity, the participants should be able to: 

• Review the latest advancements in understanding molecular and cellular mechanisms that drive early lung carcinogenesis
• Examine preclinical and clinical advances in early-stage lung cancer
• Evaluation the basic research on oncogenesis and biology of disease, preclinical therapeutic research, and highlights of ongoing clinical translation. 
• Provide researchers and medical oncologists with the knowledge needed to innovate and improve patient outcomes.

• Tom John, MD, PhD, Peter MacCallum Cancer Centre | Australia
• Celine Mascaux, MD, PhD, Hopitaux Universitaires de Strasbourg | France
• Testuya Mitsudomi MD, PhD, Izumi City General Hospital | Japan
• Triparna Sen, MD, MS, The Ohio State University | USA
• Aaron Tan, MD, PhD, National Cancer Centre Singapore | Singapore

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For assistance with this activity, please email: education@iaslc.org.